中国肺癌杂志最新文献

{"title":"[Mechanism of NUF2 in Promoting NSCLC Progression \u2029through the Regulation of Ferroptosis].","authors":"Yani Liu, Jiaxuan Ren, Ruibin Zhao, Xiaoru Ma, Yunbo Di, Yirong Xu, Zhenwen Chen","doi":"10.3779/j.issn.1009-3419.2026.106.23","DOIUrl":"https://doi.org/10.3779/j.issn.1009-3419.2026.106.23","url":null,"abstract":"<p><strong>Background: </strong>NUF2 component of NDC80 kinetochore complex (NUF2) is a core regulatory protein that ensures proper chromosome segregation, and its aberrant expression is closely associated with cancer initiation and progression. Although the expression level of NUF2 is higher in non-small cell lung cancer (NSCLC) than in normal tissues, its mechanism of action in NSCLC remains unclear. This study aims to investigate the mechanism by which NUF2 promotes the proliferation, migration, and invasion of NSCLC.</p><p><strong>Methods: </strong>The expression differences of NUF2 between NSCLC and normal lung tissues as well as the correlation between NUF2 expression and overall survival (OS) of NSCLC patients were analyzed via the Gene Expression Profiling Interactive Analysis (GEPIA) database. Immunohistochemical (IHC) staining was performed to detect the positive expression rate of NUF2 in NSCLC specimens. NUF2 knockdown and overexpression stable cell lines were established in the A549 cell line, and transfection efficiency was verified by Western blot (WB) and quantitative real-time polymerase chain reaction (RT-qPCR). The proliferation, migration, and invasion of transfected cells were assessed using the cell counting kit-8 (CCK-8), colony formation assay, wound healing assay, and Transwell assay. The expression levels of ferroptosis-related proteins were determined using WB and RT-qPCR. Commercial assay kits were utilized to measure the contents of malondialdehyde (MDA), reactive oxygen species (ROS), ferrous ion (Fe²+) and glutathione (GSH), while intracellular mitochondrial structural alterations were visualized by transmission electron microscopy (TEM). Xenograft tumor models were established. The expression levels of NUF2, SLC7A11 and ACSL4 were detected by WB, RT‑qPCR and IHC.</p><p><strong>Results: </strong>GEPIA analysis revealed that NUF2 was significantly highly expressed in NSCLC (P<0.05) and was associated with OS (P<0.001). Clinical statistical analyses demonstrated that upregulated NUF2 was significantly associated with advanced clinical stage (P<0.05) and lymph node metastasis (P<0.01). NUF2 knockdown markedly suppressed the proliferation, migration and invasion of NSCLC cells (P<0.001) and reduced xenograft tumor volume in vivo (P<0.05). Mechanistically, NUF2 silencing downregulated the expression of the ferroptosis master regulator SLC7A11 (P<0.01) while upregulating ACSL4 (P<0.01). The levels of MDA (P<0.01), ROS and Fe²+ (P<0.001) were all elevated following NUF2 knockdown, while the content of GSH decreased (P<0.001). TEM observation revealed that NUF2 knockdown led to mitochondrial shrinkage, reduced cristae number and increased membrane density. Conversely, NUF2 overexpression enhanced NSCLC cell proliferation, migration and invasion (P<0.001) and increased xenograft tumor volume (P<0.001). Meanwhile, SLC7A11 expression was elevated (P<0.01) and ACSL4 expression was decreased (P<0.01). The levels of ROS (P<0.001)","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"29 8","pages":"557-569"},"PeriodicalIF":0.0,"publicationDate":"2026-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149224964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Evolution of Perioperative Immunotherapy Paradigms in Non-small Cell Lung Cancer: From Adjuvant Dilemma to Neoadjuvant Priority].","authors":"Jie Xu, Zhansheng Jiang","doi":"10.3779/j.issn.1009-3419.2026.102.25","DOIUrl":"https://doi.org/10.3779/j.issn.1009-3419.2026.102.25","url":null,"abstract":"<p><p>The application of immune checkpoint inhibitors (ICIs) has reshaped the perioperative treatment pattern of resectable non-small cell lung cancer (NSCLC). Currently, three treatment paradigms have emerged: adjuvant, neoadjuvant alone, and 'sandwich' (neoadjuvant+surgery+adjuvant). Although IMpower010 and KEYNOTE-091 achieved positive results in adjuvant immunotherapy, the negative results of two large phase III studies, BR.31 and ANVIL, raised questions about the generalizability of this model. In contrast, neoadjuvant immunotherapy has shown efficacy in multiple phase III studies. This advantage may stem from the preservation of the intact tumor antigen repertoire and draining lymph node architecture, enabling chemo-immunotherapy to elicit more robust systemic immune responses. Currently, both neoadjuvant alone and 'sandwich' models are recommended by guidelines, but the 5-year overall survival (OS) rates of CheckMate-816 and KEYNOTE-671 are nearly identical (65.4% vs 64.6%), and the pathological complete response (pCR) rate of CheckMate-77T (25.3%) is comparable to that of CheckMate-816 (24%), suggesting that the incremental benefit of extending neoadjuvant cycles and adding postoperative adjuvant immunotherapy in the 'sandwich' model is very limited. In the future, an individualized decision-making model based on pCR and molecular residual disease (MRD) status, such as de-escalation to observation for those achieving pCR with negative MRD, and intensification for those with residual disease or positive MRD, is expected to optimize the balance between treatment intensity and survival benefit. In summary, the existing evidence favors the adoption of a 'neoadjuvant first' strategy for resectable NSCLC. Based mainly on cross-trial indirect comparisons, the neoadjuvant alone model offers comparable efficacy to the 'sandwich' approach with potential cost-effectiveness advantages, and may be preferred as the initial strategy. Individualized post-neoadjuvant management represents the future direction of this field.\u2029.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"29 8","pages":"617-624"},"PeriodicalIF":0.0,"publicationDate":"2026-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149224931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Analysis of Clinical Characteristics in 49 Patients of Lung Cancer \u2029Combined with Interstitial Lung Disease].","authors":"Jing Zhao, Lihua Zhao, Xiaoxing Gao, Xiaoyan Liu, Yan Xu, Minjiang Chen, Wei Zhong, Mengzhao Wang","doi":"10.3779/j.issn.1009-3419.2026.106.25","DOIUrl":"https://doi.org/10.3779/j.issn.1009-3419.2026.106.25","url":null,"abstract":"<p><strong>Background: </strong>The patients of lung cancer combined with interstitial lung disease (LC-ILD) account for a high proportion, and their prognosis is poor. Currently, no standard treatment regimen had been established for this population. This study aimed to summarize the clinical characteristics and treatment outcomes of patients with LC-ILD, and to explore factors associated with marked ILD progression under different tumor treatment strategies.</p><p><strong>Methods: </strong>The clinical characteristics, tumor treatment, and follow-up data of 49 LC-ILD patients hospitalized in the Department of Pulmonary and Critical Care Medicine at Peking Union Medical College Hospital from January 2018 to December 2024 were collected. The efficacy and follow-up outcomes of different treatment modalities were observed; the survival analysis was performed, and the potential influencing factors for the significant progression of ILD were analyzed.</p><p><strong>Results: </strong>LC-ILD is most commonly of the usual interstitial pneumonia (UIP) pattern, with tumors frequently located in fibrotic regions. The median progression-free survival (PFS) was 7.0 months for advanced non-small cell lung cancer (NSCLC) and 4.0 months for small cell lung cancer (SCLC). Of the 36 patients with completed follow-up and treatment, 10 showed radiographic progression of interstitial lesions, with 4 deaths occurring in this subgroup. Logistic regression analysis indicated that radiotherapy was significantly correlated radiological progression of ILD (P<0.05).</p><p><strong>Conclusions: </strong>For patients with LC-ILD, individualized evaluation including chest high resolution computed tomography and pulmonary function test (particularly diffusing capacity) should be performed before initiating therapy. The therapeutic approach should balance efficacy and safety, and special attention should be given to the risk of radiological progression of ILD associated with radiotherapy.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"29 8","pages":"586-592"},"PeriodicalIF":0.0,"publicationDate":"2026-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149224845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Mechanisms and Clinical Translation Advances of Physical Targeted Therapy \u2029for Malignant Pleural Effusion].","authors":"Jia Zhao, Zhenyu Yin, Xin Hua","doi":"10.3779/j.issn.1009-3419.2026.101.20","DOIUrl":"https://doi.org/10.3779/j.issn.1009-3419.2026.101.20","url":null,"abstract":"<p><p>Malignant pleural effusion (MPE) is a common severe complication of advanced lung cancer and significantly worsens prognosis. Physical targeted therapies, represented by piezocatalytic therapy, sonodynamic therapy, photodynamic therapy, hyperthermic intrathoracic chemotherapy, radiofrequency ablation and thermosensitive in situ hydrogel drug delivery system, induce reactive oxygen species generation via light, ultrasound, or piezocatalytic energy, or achieve tumor killing through local hyperthermia and temperature-controlled drug release, offering new strategies for MPE. However, existing reviews mostly focus on single modalities, lacking systematic classification and suitability comparison based on the pleural microenvironment and respiratory mechanics. This review summarizes their mechanisms, biological effects, and translational status in the context of pleural anatomy and pathological microenvironment, and highlights multi-field combination, microenvironment remodeling, and precise energy regulation as future directions for MPE therapy.\u2029.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"29 8","pages":"601-608"},"PeriodicalIF":0.0,"publicationDate":"2026-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149225004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Advances on Postoperative Recurrence Risk Prediction in Non-small Cell Lung Cancer].","authors":"Shihang Zhang, Haitao Yang, Zhibin Huang, Baosong Xie","doi":"10.3779/j.issn.1009-3419.2026.101.21","DOIUrl":"https://doi.org/10.3779/j.issn.1009-3419.2026.101.21","url":null,"abstract":"<p><p>Lung cancer remains the malignant tumor with the highest incidence and mortality rates worldwide, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of cases. Radical surgical resection serves as the primary curative modality for patients with resectable NSCLC; however, postoperative recurrence persists in a subset of patients, thereby compromising long-term survival outcomes. Consequently, the precise prediction of postoperative recurrence risk, identification of high-risk populations, and formulation of individualized adjuvant therapy and surveillance strategies are of paramount importance for improving patient prognosis. In recent years, fueled by the rapid evolution of artificial intelligence (AI) and liquid biopsy technologies, the prediction of postoperative recurrence in NSCLC has progressively transitioned toward greater precision and personalization. This review summarizes the current applications of traditional predictive models, AI-based models, and liquid biopsy techniques in forecasting NSCLC recurrence following surgery, evaluating their respective strengths and limitations. Furthermore, it provides insights into future research trajectories.\u2029.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"29 8","pages":"609-616"},"PeriodicalIF":0.0,"publicationDate":"2026-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149225147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Prognostic Models and Clinical Translation Prospects of Lung Cancer \u2029Based on Novel Cell Death Modes].","authors":"Linjie Sun, Yunkai You, Ying Zhang, Xintong Jiang, Shuyang Xie, Pingyu Wang","doi":"10.3779/j.issn.1009-3419.2026.101.19","DOIUrl":"https://doi.org/10.3779/j.issn.1009-3419.2026.101.19","url":null,"abstract":"<p><p>As one of the malignant tumors with high incidence and mortality worldwide, lung cancer features high heterogeneity and therapeutic resistance, which severely impair the prognosis of patients with lung cancer. In recent years, novel cell death modes such as ferroptosis, cuproptosis, disulfidptosis and necrosis by sodium overload have become research hotspots in oncology. Focusing on these four forms of cell death, this review systematically clarifies their roles in lung cancer initiation and progression, regulation of the tumor microenvironment, and therapeutic resistance; summarizes related prognostic biomarkers and representative prognostic models; and discusses the crosstalk among multiple cell death pathways and advances in clinical translation. This review aims to provide a reference for improving prognostic assessment in lung cancer, elucidating mechanisms of therapeutic resistance, and developing novel antitumor strategies.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"29 8","pages":"593-600"},"PeriodicalIF":0.0,"publicationDate":"2026-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149224966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Clinical Efficacy of A Novel CT-based Localization Method for Totally Implantable \u2029Venous Access Port Placement in Lung Cancer via Internal Jugular Vein].","authors":"Dian Ren, Wenhao Zhao, Dinghuan Zhao, Tong Li, Yu Hua, Jing Wang, Jiachen Hu, Yajun Wang, Song Du, Lingyu Guo, Yajie Cui, Mei Li, Huihui Ji, Yi Shi, Xin Li, Jun Chen","doi":"10.3779/j.issn.1009-3419.2026.102.23","DOIUrl":"https://doi.org/10.3779/j.issn.1009-3419.2026.102.23","url":null,"abstract":"<p><strong>Background: </strong>Implantable venous ports can substantially reduce venous access-related complications in patients undergoing chemotherapy for lung cancer. However, accurate positioning of the catheter tip at the cavoatrial junction (CAJ), defined as the anatomical junction between the superior vena cava (SVC) and right atrium, remains technically challenging. Although electrocardiography (ECG)-guided positioning is widely used in clinical practice, the technique can be relatively complex and time-consuming. Based on clinical practice, we developed a novel computed tomography (CT)-based positioning technique and aimed to evaluate its clinical efficacy and positioning accuracy.</p><p><strong>Methods: </strong>We retrospectively analyzed 40 patients with lung cancer who underwent implantable port placement via the internal jugular vein at the Department of Lung Cancer Surgery, Tianjin Medical University General Hospital, between January 2024 and April 2026. The patients were divided into two groups according to the catheter tip positioning technique: the CT-guided positioning group (n=20) and the ECG-guided positioning group (n=20). Postoperative CT imaging was performed to measure the distance between the catheter tip and the CAJ. The accuracy and variability of catheter tip positioning were compared between the two groups. In addition, the surface anatomical landmarks corresponding to the internal jugular vein puncture site and the CAJ were recorded and analyzed.</p><p><strong>Results: </strong>Compared with the ECG-guided group, the CT-guided group demonstrated significantly greater catheter tip positioning accuracy and lower positional variability (P=0.009). The seventh cervical spinous process (C7) was the most common surface anatomical landmark corresponding to the internal jugular vein puncture site. The surface projection of the CAJ was predominantly located at the level of the 4th costal cartilage and the 4th intercostal space on the anterior chest wall and the 7th-8th costal cartilage level on the posterior thoracic wall.</p><p><strong>Conclusions: </strong>The novel CT-based positioning technique demonstrated greater accuracy and consistency in catheter tip placement than ECG-guided positioning in patients undergoing internal jugular vein port implantation.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"29 8","pages":"580-585"},"PeriodicalIF":0.0,"publicationDate":"2026-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149224895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Diagnosis and Intraoperative Decision-making in Pulmonary Sclerosing Pneumocytoma with Atypical Imaging Findings: A Case Report and Review of the Literature].","authors":"Xingyi Xu, Hui Xiao, Xiong Ye","doi":"10.3779/j.issn.1009-3419.2026.101.22","DOIUrl":"https://doi.org/10.3779/j.issn.1009-3419.2026.101.22","url":null,"abstract":"<p><p>Pulmonary sclerosing pneumocytoma (PSP) is a rare benign pulmonary tumor that predominantly occurs in middle-aged women. Its preoperative diagnosis remains challenging, and it is frequently misdiagnosed as a malignant tumor. Herein, we report a case of PSP with atypical imaging manifestations and review the current literature on this entity. A 68-year-old woman presented with chest tightness. Chest computed tomography (CT) revealed a lobulated solid nodule in the right middle lobe measuring approximately 26 mm × 22 mm, accompanied by multiple enlarged lymph nodes in the bilateral hilar, mediastinal, and axillary regions. The diagnosis of PSP was confirmed by postoperative histopathology. Based on the features of this case and review of the relevant literature, we suggest that when a patient presents with clinical features suggestive of PSP and intraoperative frozen-section hematoxylin and eosin staining predominantly shows a single solid or papillary architecture in which the surface and stromal cells are difficult to distinguish, intraoperative rapid immunohistochemistry may be performed to improve diagnostic accuracy and avoid excessive surgical resection.\u2029.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"29 8","pages":"630-634"},"PeriodicalIF":0.0,"publicationDate":"2026-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149224862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Variant Allele Frequency Stratification and EGFR Co-mutation Characteristics \u2029in AKT1 E17K-mutant Non-small Cell Lung Cancer].","authors":"Dan Zhao, Deyang Xie, Nana Zhang, Lili Zhang, Kun Li, Nanying Che","doi":"10.3779/j.issn.1009-3419.2026.106.24","DOIUrl":"https://doi.org/10.3779/j.issn.1009-3419.2026.106.24","url":null,"abstract":"<p><strong>Background: </strong>AKT serine/threonine kinase 1 (AKT1) E17K, the most common activating mutation of AKT1, is an established druggable driver in breast cancer; however, it is exceedingly rare in non-small cell lung cancer (NSCLC), with its clinical significance remaining unclear. Variant allele frequency (VAF) may partially reflect the clonal proportion of a mutation, offering clues to the clonal characteristics of such rare mutations. This study investigated the relationship between AKT1 E17K VAF and co-mutation with classic driver genes such as epidermal growth factor receptor (EGFR) in NSCLC, aiming to explore the potential role of this mutation in tumor clonal evolution.</p><p><strong>Methods: </strong>Next-generation sequencing (NGS) data of lung cancer patients at Beijing Chest Hospital, Capital Medical University from June 2019 to April 2026 were retrospectively analyzed. After deduplication of 13,003 tests, 11,368 unique patients (including small cell lung cancer) were identified, among whom 35 harbored AKT1 E17K mutations (overall detection rate 0.31%), all being NSCLC; 5 external consultation cases were excluded, leaving 30 cases for analysis. Continuous VAF analysis was designated as the primary analysis, with an exploratory cutoff of 10%.</p><p><strong>Results: </strong>Of the 30 patients, 20 (66.7%) were adenocarcinoma. Median follow-up was 12 months (range: 1-55 months). The EGFR co-mutation rate was lower in the high-VAF group (≥10%, n=17) than in the low-VAF group (<10%, n=13; 11.8% vs 46.2%), reaching nominal significance before correction [P=0.049, odds ratio (OR)=0.156] but not after Bonferroni adjustment (adjusted P=0.246). The median VAF was lower in the EGFR co-mutated group than in the EGFR wild-type group (1.37% vs 13.73%, P=0.071). Continuous analysis showed a negative trend between VAF and EGFR co-mutation (ρ=-0.340, P=0.066). After adjusting for histological type using Firth-corrected Logistic regression, the direction of the association remained unchanged but was no longer nominally significant (OR=0.21, 95%CI: 0.03-1.33, P=0.097).</p><p><strong>Conclusions: </strong>AKT1 E17K VAF showed a negative trend with EGFR co-mutation; however, the association did not remain significant after correction for multiple comparisons or adjustment for histological type, and may be partly influenced by histological composition. These findings should be regarded as hypothesis-generating and require validation in larger multi-center cohorts.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"29 8","pages":"570-579"},"PeriodicalIF":0.0,"publicationDate":"2026-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149225002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Advanced Enteric-type Thymic Adenocarcinoma with Axillary Lymph Node \u2029Oligometastasis: A Case Report].","authors":"Chuan Huang, Zheng Wang, Hongfeng Tong","doi":"10.3779/j.issn.1009-3419.2026.101.18","DOIUrl":"10.3779/j.issn.1009-3419.2026.101.18","url":null,"abstract":"<p><p>Enteric‑type thymic adenocarcinoma (ETAC) is a rare subtype of thymic carcinoma. It shares highly similar histological and immunophenotypic features with intestinal adenocarcinoma, and is therefore prone to being misdiagnosed as metastatic carcinoma of gastrointestinal origin. Herein, we report a case of advanced ETAC with axillary lymph node oligometastasis. Positron emission tomography/computed tomography (PET/CT) and gastrointestinal endoscopy were performed to rule out primary gastrointestinal malignancy. The patient underwent median sternotomy with extended thymectomy, which effectively relieved superior vena cava obstruction and cardiopulmonary compressive symptoms. Postoperatively, systemic chemotherapy combined with immunotherapy, as well as regional radiotherapy targeting the primary tumor bed and metastatic lymph nodes, were administered. The patient remained disease‑free during the 24‑month postoperative follow‑up. This case suggests that aggressive local therapy combined with molecular‑subtype‑based systemic treatment may offer novel therapeutic opportunities for carefully selected patients with advanced ETAC and oligometastases.\u2029.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"29 8","pages":"625-629"},"PeriodicalIF":0.0,"publicationDate":"2026-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149225194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}